[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中华临床感染病杂志,2011,4:1-13.
[2] 慢性乙型肝炎防治指南(2015更新版中华临床感染病杂志, 2015,8:481-503.
[3] Cundy KC, Barditch-Crovo P,Walker RE, et al.Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.Antimicrobial Agents Chemother,1995,39:2401～2405.
[4] Chang TT,Gish RG,de Man R,et al.A randomized comparison of entecavir to lamivudine for treatment of HBeAg-positive chronic hepmitis B in nucleoside-naive patients.N Engl J Med,2006,354:1001-1010.
[5] Lai CL,Shouval D,Lok AS,et al.Entecavir for HBeAg negative chronic hepatitis B.A randomized comparison of entecavir to lamivudine for treatment of HBeAg-negmive chronic hepatitis B in nucleoside-naive patients.N Engl J Med,2006,354:1011-1020.
[6] Colonno R,Rose R Levine S,et al.Entecavir two year resistance update:no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients.Hepatology,2005,42(Suppl 1):573A.
[7] Zeuzem S,de Man RA,Honkoop P,et al.Dynamics of hepatitis B virus infection in vivo.J Hepatology, 1997,27:43 1-436. |
